North Natomas just handed over one of its key industrial addresses to its longtime tenant, as Nivagen Pharmaceuticals has bought the building it already occupies at 3900 Duckhorn Drive in Sacramento. The deal pulls ownership of the sterile injectable manufacturing site into local hands and effectively completes the transfer of Panattoni's Natomas Advanced Logistics Center to its users, giving the Sacramento-based company full control of the facility where it makes IV bags, vials and prefilled syringes.
According to the Sacramento Business Journal, Panattoni Development Company Inc. sold the final piece of the Natomas Advanced Logistics Center to Nivagen, its existing tenant. The outlet reports that the sale shifts ownership of the building that houses Nivagen's sterile manufacturing operation to the company itself, although neither side has revealed the purchase price.
Nivagen's Natomas Manufacturing Hub
Nivagen runs a roughly 100,000-square-foot cGMP sterile-injectables plant in Sacramento that can turn out IV bags, vials, prefilled syringes and cartridges, according to the company's website. In early January, private-equity-backed PAI Pharma announced that it had acquired Nivagen and spotlighted the firm's aseptic production capability and pipeline of ready-to-use sterile injectable products. Supporters of that transaction have framed it as part of a broader effort to onshore key drug manufacturing and bolster hospital supply chains.
Where The Building Fits In Natomas
Developer Panattoni built the two-building Natomas Advanced Logistics Center along Duckhorn Drive and had previously sold the neighboring 3950 Duckhorn Drive as part of a planned selloff of the project, according to the company's materials. With 3900 Duckhorn now also in the hands of its tenant, Panattoni appears to have wrapped up its role at the compact industrial complex.
What This Could Mean For Sacramento
By owning the property instead of leasing it, Nivagen gains more room to maneuver. The company can rework production lines or pour money into additional capacity without working through a separate landlord, which is a practical edge for a business centered on sterile injectables. Industry and policy voices have repeatedly flagged domestic sterile-injectable capacity as a national priority, a theme that PAI Pharma also stressed when it rolled out news of its Nivagen acquisition.
Deal Details And Next Steps
For now, the financial specifics remain under wraps. Neither Panattoni nor Nivagen has made the sale price public, and the Sacramento Business Journal reports that the companies did not immediately offer further comment. Nivagen's earlier press filings indicate that the firm sold its MedisourceRx unit in 2024 and used the proceeds to help expand its sterile manufacturing footprint, according to a Business Wire release.
